← Back to patent-cliff list
Diclofenac sodium transdermal patch (Hisamitsu Pharmaceuticals)
Tier C — Watch / tradeDiclofenac sodium transdermal patch (Hisamitsu Pharmaceuticals)
Hisamitsu Pharmaceutical Co., Inc.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COXs
Indications (approved)：Cancer pain, Pain, Back pain, Knee arthritis
Regional status
US
Phase III
2020-12-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Diclofenac sodium transdermal patch (Hisamitsu Pharmaceuticals)?
Approved indications include: Cancer pain, Pain, Back pain, Knee arthritis.
When does the Diclofenac sodium transdermal patch (Hisamitsu Pharmaceuticals) patent expire?
No public expiry year is available for Diclofenac sodium transdermal patch (Hisamitsu Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Diclofenac sodium transdermal patch (Hisamitsu Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06